Early outcomes following low dose naltrexone enhancement of opioid detoxification.
Repository Usage Stats
Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone taper was recently associated with attenuated withdrawal intensity during detoxification. We describe the results of a seven-day follow-up evaluation of 96 subjects who completed inpatient detoxification consisting of the addition of VLNTX (0.125 or 0.250 mg per day) or placebo to methadone taper in a double blind, randomized investigation. Individuals receiving VLNTX during detoxification reported reduced withdrawal and drug use during the first 24 hours after discharge. VLNTX addition was also associated with higher rates of negative drug tests for opioids and cannabis and increased engagement in outpatient treatment after one week. Further studies are needed to test the utility of this approach in easing the transition from detoxification to various follow-up treatment modalities designed to address opioid dependence.
Substance Withdrawal Syndrome
Continuity of Patient Care
Published Version (Please cite this version)10.1080/10550490902772785
Publication InfoMannelli, Paolo; Patkar, Ashwin A; Peindl, Kathleen; Gottheil, Edward; Wu, Li-Tzy; & Gorelick, David A (2009). Early outcomes following low dose naltrexone enhancement of opioid detoxification. The American journal on addictions, 18(2). pp. 109-116. 10.1080/10550490902772785. Retrieved from https://hdl.handle.net/10161/20046.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Associate Professor of Psychiatry and Behavioral Sciences
Professor of Psychiatry and Behavioral Sciences
Assistant Consulting Professor in the Department of Psychiatry and Behavioral Sciences
Professor in Psychiatry and Behavioral Sciences
Education/Training: Pre- and post-doctoral training in mental health service research, psychiatric epidemiology (NIMH T32), and addiction epidemiology (NIDA T32) from Johns Hopkins University School of Public Health (Maryland); Fellow of the NIH Summer Institute on the Design and Conduct of Randomized Clinical Trials.Director: Duke Community Based Substance Use Disorder Research Program.Research interests: COVID-19, Opioid misuse, Opioid overdose, Opioid use disorder
Alphabetical list of authors with Scholars@Duke profiles.